MICA: An evaluation of the antimalarial vaccine candidateR21/matrix M for malaria elimination strategy in the Greater Mekong Subregion

MICA：针对大湄公河次区域疟疾消除战略的抗疟候选疫苗 R21/matrix M 的评估

• 批准号: MR/T04473X/1
• 负责人: Lorenz Von Seidlein
• 金额: $ 37.6万
• 依托单位: University of Oxford
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FT04473X%2F1
• 关键词: MICA; evaluation; antimalarial; vaccine; candidateR21

We are proposing the evaluation of the new vaccine candidate R21 with matrix-M adjuvant as a malaria elimination tool for the Greater Mekong Subregion. Existing malaria control tools have driven falciparum malaria transmission to very low levels. The addition of mass drug administrations has reduced and even interrupted transmission for short time spans. A vaccine which can confer protection for a longer, albeit limited, time period may be sufficient to interrupt malaria transmission permanently on a regional level.To roll out mass vaccine administrations on a regional level it is necessary to demonstrate that vaccine is well tolerated and triggers the desired immune response when co-administered with antimalarial drugs in the the people currently at risk for malaria in the Greater Mekong Subregion. We propose here a healthy volunteer study to demonstrate that the vaccine candidate R21 with matrix-M is well tolerated and immunogenic in Thailand. This study will be conducted in healthy volunteers at Mahidol University, Bangkok, Thailand. The vaccine regimen will consist of three vaccine doses one month apart. Each vaccine dose will be combined with three doses of antimalarial drugs (dihydroartemisinin / piperaquine and a single low dose primaquine). Study participants will be followed for 6 months to assess their well being and immune responses.If successful we will proceed to the next, larger trial to see whether the vaccine co-administered with antimalarial drugs protects against falciparum malaria, but that will be separate grant application.

我们提出了对新疫苗候选R21的评估，该疫苗R21用基质-M佐剂作为更大的湄公河区域的疟疾消除工具。现有的疟疾控制工具将恶性疟疾的传播驱动到非常低的水平。大规模药物管理局的增加减少甚至在短时间内中断了传播。一种疫苗，可以允许更长（尽管有限的时间）提供保护的疫苗，但时间段可能足以在区域层面上永久中断疟疾传播。要在区域级别上推出大量疫苗管理，有必要证明疫苗的耐受性良好并触发触发因素与当前在更大湄公河区域中有疟疾风险的人共同采用抗疟药时，所需的免疫反应。我们在这里提出了一项健康的志愿者研究，以证明泰国具有良好的疫苗候选R21的疫苗R21。这项研究将在泰国曼谷Mahidol大学的健康志愿者中进行。疫苗方案将包括三个疫苗剂量相隔一个月。每种疫苗剂量将与三剂抗疟药（二羟基氨基蛋白 /哌啶和一个单一的低剂量primaquine）结合使用。研究参与者将被遵循6个月以评估其健康和免疫反应。如果成功进行下一个更大的试验，以查看是否与抗疟药共同采用疫苗是否可以保护恶性疟疾，但这将是单独的赠款应用。